Cost and morbidity of MRSA in head and neck cancer patients: What are the consequences?

Journal of Laryngology and Otology

Volumn 118, Issue 9, 2004, Pages 694-699

  Watters, K ^a   O'Dwyer, T P ^a   Rowley, H ^a,b  

^a MATER PRIVATE HOSPITAL   (Ireland)

^b Swords Co   (Ireland)

Author keywords

Head and Neck Neoplasms; Health Resources; Methicillin Resistance; Morbidity; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; PSEUDOMONIC ACID; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; BACTERIAL COLONIZATION; CELLULITIS; CLINICAL ARTICLE; DEBRIDEMENT; DRUG COST; FEMALE; HEAD AND NECK CANCER; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; NURSING; OSTEOMYELITIS; PNEUMONIA; RETROSPECTIVE STUDY; REVIEW; STAPHYLOCOCCUS INFECTION;

EID: 7044285869     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1258/0022215042244732     Document Type: Review

References (20)

1. Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrobial Agents 2000;16(suppl 1):3-10
2. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104
3. Lane WR. Methicillin resistance in staphylococci. Med J Australia 1962;49:962
4. Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, Joh Kauffman CA, Yu VL. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993;94:313-28
5. Doebbeling BN. The epidemiology of methicillin resistant Staphylococcus aureus colonisation and infection. J Chemother 1995;7(suppl 3):99-103
6. Swift AC. Wound sepsis, chemoprophylaxis and major head and neck surgery. Clin Otolaryngol 1988;13:81-3
7. Parton M, Beasley NJP, Harvey G, Houghton D, Jones AS. Four cases of aggressive MRSA wound infection following head and neck surgery. J Laryngol Otol 1997;3:874-6
8. Tungekar MF. Tracheocarotid artery fistula infected with methicillin resistant Staphylococcus aureus. J Laryngol Otol 1999;113:689-91
9. Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrobial Chemother 1999;44 (suppl A):31-6
10. Marchese A, Scito GC, Debbin EA. Evolution of antibiotic resistance in gram positive pathogens. J Chemotherapy 2000;12:459-62
11. Livermore DM. Epidemiology of antibiotic resistance. Intensive Care Med 2000;26(suppl 1):14-21
12. Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother 2000;12:21-5
13. O'Connell NH, Humphreys H. Intensive care unit design and environmental factors in the acquisition of infection. J Hosp Infect 2000;45:255-62
14. Vincent JL, Bihari DJ, Suter PM. The prevalence of nosocomial infection in intensive care in Europe. JAMA 1995;274:639-44
15. Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 1999;20:473-7
16. Chaix C, Durand-Zaleski I, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in intensive care. JAMA 1999;282:1745-51
17. Johnson KD, Johnston DW. Orthopaedic experience with MRSA during a hospital epidemic. Clin Orthopaed 1986;212:281-8
18. Cheng AF, French G. Methicillin-resistant Staphylococcus aureus bacteraemia in Hong Kong. J Hosp Infect 1988;12:91-101
19. Report of a Combined Working Party of the Hospital Infection Society. Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect 1990;16:351-77
20. Public Health Laboratory Service (PHLS). The Socio-Economic Burden of Hospital Acquired Infection. London: PHLS, 1999